An interventional study of Aerobic exercise for >_75 minutes/week of vigorous aerobic exercise or >_ 150 minutes/week of moderate aerobic exercise in at least two weekly sessions, for 12 m in Parkinson Disease, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 1 site in Italy. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-23.
Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Parkinson Disease by Fondazione Policlinico Universitario Agostino Gemelli IRCCS — 9 open to participants now, 9 under way, none of them phase 3. Parkinson Disease · Fondazione Policlinico Universitario Agostino Gemelli IRCCS.
Among the 14 studies in Parkinson Disease by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, this one is the 3rd largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2025, is one of 10 with no phase, and was the 12th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →9 of the 14 studies in Parkinson Disease by Fondazione Policlinico Universitario Agostino Gemelli IRCCS are open now, in 1 country. Recruiting first, the newest first:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 30–80
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18 mo+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 30–80
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+ · Healthy volunteers
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18–80
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 150 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 53 across the 10 interventional studies, 57 across the 4 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the lead sponsor of 953 studies on the registry; 541 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Parkinson Disease by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Cognitive impairment is an acknowledged feature of Parkinson's disease (PD) and often coexists with the classic motor symptoms since their onset. Cognitive symptoms of PD can be differentiated from other neurodegenerative diseases by the affected domains: typically, the executive functions are primarily affected, to a greater extent than the mnesic ones. PD-MCI is of utmost clinical relevance, as it impacts the patients' quality of life and as the major predictor for conversion to PDD. To date, there are no routinely recommended interventions to address MCI in PD and prevent it from evolving into dementia. Recent evidence supports the benefit of aerobic exercise on motor symptoms of PD and its possible disease-modifying role, through functional and structural brain changes. Less is known about the impact of aerobic exercise on cognition in the PD population. In the last decade, studies have proven aerobic exercise as a promising strategy to alter the trajectory of cognitive decline in subjects with cognitive impairment and in elderly people. In particular, executive functions were ameliorated by exercise intervention to a greater extent. A recent preclinical study also demonstrated a reduced spread of toxic alpha-synuclein (a-syn) species to vulnerable brain areas, along with the restoration of the striatal synaptic plasticity. Nonetheless, the feasibility and efficacy of an unsupervised monitored exercise program on cognition for PD-MCI subjects has not been explored yet. In this project, we will test the hypothesis that extensive homebased exercise may improve cognition in MCI-PD through a reduction of neuroinflammation and a-syn spreading via the activation of BDNF-related pathways. Motor, non-motor and cognitive evaluations, associated with measures of a-syn species, inflammation-related molecules and neurofilaments light chain in blood samples will be performed in a multicenter cohort, before and after the prescription of moderate/vigorous aerobic home-based exercise for 12 months and in a sedentary control population. Adherence to the protocol will also be evaluated. This will shed light on the impact of physical activity prescription in the care of people with PD, addressing one of the most unmet needs in PD, since no disease-modifying treatments are available for cognitive deficits to date.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The EG will be prescribed aerobic exercise for \>\_ 75 minutes/week of vigorous aerobic exercise (60%-85% of HR MAX) or \>\_150 minutes/week of moderate aerobic exercise (40%-60% of HR MAX) in at least two weekly sessions, for 12 months.
Behavioral: Aerobic exercise for >_75 minutes/week of vigorous aerobic exercise or >_ 150 minutes/week of moderate aerobic exercise in at least two weekly sessions, for 12 m
The SG will be told to continue their routine daily activities and will be followed up regularly at the outpatient clinic.
Participants will use a commercially available wearable device with a heart rate monitor to prove adherence to the program and record the intensity of all exercise sessions.
Motor performance
· Unified Parkinson's Disease Rating Scale - MDS (MDS-UPDRS) to evaluate various aspects of PD, including non-motor and motor experiences of daily living and motor complications (0-272, the higher, the worse)
Time frame: From enrollment (time 0) to the end of exercise (after 12 months)
non motor assessment
· MDS - Non-Motor Symptoms Rating Scale (MDS-NMS) which measures the severity and frequency of non-motor symptoms (0-360, the higher, the worse)
Time frame: From enrollment (time 0) to the end of exercise (after 12 months)
disease stage
· Hoehn and Yahr stage (H\&Y), to assess disease stage (1-4, the higher the worse)
Time frame: From enrollment (time 0) to the end of exercise (after 12 months)
Cognitive evaluation
. Montreal Cognitive assessment (0-30, the lower the worse)
Time frame: From enrollment (time 0) to the end of exercise (after 12 months)
Biochemical analysis of biomarkers
Studying changes in biomarkers of inflammation and neurodegeneration in people with Parkinson's disease following a home exercise program (serum levels of IL1B, IL4, IL5, IL6, IL10, IL17, IFN-gamma, TNF-alpha, total alpha synuclein)
Time frame: From enrollment (time 0) to the end of exercise (after 12 months)
Started Jun 2025 (actual). Primary completion is estimated for Apr 2028, 34 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 34 months is above that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS →